241 related articles for article (PubMed ID: 28320590)
1. MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice.
Davtyan H; Chen WW; Zagorski K; Davis J; Petrushina I; Kazarian K; Cribbs DH; Agadjanyan MG; Blurton-Jones M; Ghochikyan A
Vaccine; 2017 Apr; 35(16):2015-2024. PubMed ID: 28320590
[TBL] [Abstract][Full Text] [Related]
2. Active immunization with tau epitope in a mouse model of tauopathy induced strong antibody response together with improvement in short memory and pSer396-tau pathology.
Joly-Amado A; Davtyan H; Serraneau K; Jules P; Zitnyar A; Pressman E; Zagorski K; Antonyan T; Hovakimyan A; Paek HJ; Gordon MN; Cribbs DH; Petrovsky N; Agadjanyan MG; Ghochikyan A; Morgan D
Neurobiol Dis; 2020 Feb; 134():104636. PubMed ID: 31629891
[TBL] [Abstract][Full Text] [Related]
3. Testing a MultiTEP-based combination vaccine to reduce Aβ and tau pathology in Tau22/5xFAD bigenic mice.
Davtyan H; Hovakimyan A; Kiani Shabestari S; Antonyan T; Coburn MA; Zagorski K; Chailyan G; Petrushina I; Svystun O; Danhash E; Petrovsky N; Cribbs DH; Agadjanyan MG; Blurton-Jones M; Ghochikyan A
Alzheimers Res Ther; 2019 Dec; 11(1):107. PubMed ID: 31847886
[TBL] [Abstract][Full Text] [Related]
4. The MultiTEP platform-based Alzheimer's disease epitope vaccine activates a broad repertoire of T helper cells in nonhuman primates.
Davtyan H; Ghochikyan A; Petrushina I; Hovakimyan A; Davtyan A; Cribbs DH; Agadjanyan MG
Alzheimers Dement; 2014 May; 10(3):271-83. PubMed ID: 24560029
[TBL] [Abstract][Full Text] [Related]
5. Alzheimer's disease Advax(CpG)- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Aβ pathological molecules.
Davtyan H; Zagorski K; Rajapaksha H; Hovakimyan A; Davtyan A; Petrushina I; Kazarian K; Cribbs DH; Petrovsky N; Agadjanyan MG; Ghochikyan A
Sci Rep; 2016 Jul; 6():28912. PubMed ID: 27363809
[TBL] [Abstract][Full Text] [Related]
6. Active full-length DNA Aβ
Rosenberg RN; Fu M; Lambracht-Washington D
Alzheimers Res Ther; 2018 Nov; 10(1):115. PubMed ID: 30454039
[TBL] [Abstract][Full Text] [Related]
7. Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach.
Troquier L; Caillierez R; Burnouf S; Fernandez-Gomez FJ; Grosjean ME; Zommer N; Sergeant N; Schraen-Maschke S; Blum D; Buee L
Curr Alzheimer Res; 2012 May; 9(4):397-405. PubMed ID: 22272619
[TBL] [Abstract][Full Text] [Related]
8. A MultiTEP platform-based epitope vaccine targeting the phosphatase activating domain (PAD) of tau: therapeutic efficacy in PS19 mice.
Hovakimyan A; Antonyan T; Shabestari SK; Svystun O; Chailyan G; Coburn MA; Carlen-Jones W; Petrushina I; Chadarevian JP; Zagorski K; Petrovsky N; Cribbs DH; Agadjanyan MG; Ghochikyan A; Davtyan H
Sci Rep; 2019 Oct; 9(1):15455. PubMed ID: 31664089
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Efficacy of Preventive and Therapeutic Vaccines Targeting the N Terminus of β-Amyloid in an Animal Model of Alzheimer's Disease.
Petrushina I; Davtyan H; Hovakimyan A; Davtyan A; Passos GF; Cribbs DH; Ghochikyan A; Agadjanyan MG
Mol Ther; 2017 Jan; 25(1):153-164. PubMed ID: 28129111
[TBL] [Abstract][Full Text] [Related]
10. Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis.
Selenica ML; Davtyan H; Housley SB; Blair LJ; Gillies A; Nordhues BA; Zhang B; Liu J; Gestwicki JE; Lee DC; Gordon MN; Morgan D; Dickey CA
J Neuroinflammation; 2014 Sep; 11():152. PubMed ID: 25183004
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B core VLP-based mis-disordered tau vaccine elicits strong immune response and alleviates cognitive deficits and neuropathology progression in Tau.P301S mouse model of Alzheimer's disease and frontotemporal dementia.
Ji M; Xie XX; Liu DQ; Yu XL; Zhang Y; Zhang LX; Wang SW; Huang YR; Liu RT
Alzheimers Res Ther; 2018 Jun; 10(1):55. PubMed ID: 29914543
[TBL] [Abstract][Full Text] [Related]
12. MultiTEP platform-based DNA vaccines for alpha-synucleinopathies: preclinical evaluation of immunogenicity and therapeutic potency.
Davtyan H; Zagorski K; Petrushina I; Kazarian K; Goldberg NRS; Petrosyan J; Blurton-Jones M; Masliah E; Cribbs DH; Agadjanyan MG; Ghochikyan A
Neurobiol Aging; 2017 Nov; 59():156-170. PubMed ID: 28870518
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial.
Davtyan H; Ghochikyan A; Petrushina I; Hovakimyan A; Davtyan A; Poghosyan A; Marleau AM; Movsesyan N; Kiyatkin A; Rasool S; Larsen AK; Madsen PJ; Wegener KM; Ditlevsen DK; Cribbs DH; Pedersen LO; Agadjanyan MG
J Neurosci; 2013 Mar; 33(11):4923-34. PubMed ID: 23486963
[TBL] [Abstract][Full Text] [Related]
14. Delivery of a DNA vaccine for Alzheimer's disease by electroporation versus gene gun generates potent and similar immune responses.
Davtyan H; Ghochikyan A; Movsesyan N; Ellefsen B; Petrushina I; Cribbs DH; Hannaman D; Evans CF; Agadjanyan MG
Neurodegener Dis; 2012; 10(1-4):261-4. PubMed ID: 22301697
[TBL] [Abstract][Full Text] [Related]
15. Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease.
Qu B; Rosenberg RN; Li L; Boyer PJ; Johnston SA
Arch Neurol; 2004 Dec; 61(12):1859-64. PubMed ID: 15596606
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for Alzheimer's disease: DNA- and protein-based epitope vaccines.
Davtyan H; Petrushina I; Ghochikyan A
Methods Mol Biol; 2014; 1143():259-81. PubMed ID: 24715293
[TBL] [Abstract][Full Text] [Related]
17. Refinement of a DNA based Alzheimer's disease epitope vaccine in rabbits.
Ghochikyan A; Davtyan H; Petrushina I; Hovakimyan A; Movsesyan N; Davtyan A; Kiyatkin A; Cribbs DH; Agadjanyan MG
Hum Vaccin Immunother; 2013 May; 9(5):1002-10. PubMed ID: 23399748
[TBL] [Abstract][Full Text] [Related]
18. Tau monoclonal antibody generation based on humanized yeast models: impact on Tau oligomerization and diagnostics.
Rosseels J; Van den Brande J; Violet M; Jacobs D; Grognet P; Lopez J; Huvent I; Caldara M; Swinnen E; Papegaey A; Caillierez R; Buée-Scherrer V; Engelborghs S; Lippens G; Colin M; Buée L; Galas MC; Vanmechelen E; Winderickx J
J Biol Chem; 2015 Feb; 290(7):4059-74. PubMed ID: 25540200
[TBL] [Abstract][Full Text] [Related]
19. Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody.
Albert M; Mairet-Coello G; Danis C; Lieger S; Caillierez R; Carrier S; Skrobala E; Landrieu I; Michel A; Schmitt M; Citron M; Downey P; Courade JP; Buée L; Colin M
Brain; 2019 Jun; 142(6):1736-1750. PubMed ID: 31038156
[TBL] [Abstract][Full Text] [Related]
20. Tau passive immunization inhibits not only tau but also Aβ pathology.
Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
